Findings suggest potential anti-obesity use and novel drug for treating type 2 diabetes
Type 1 diabetes is not predominantly a ‘disease of childhood’ as previously believed, but is similarly prevalent in adults, new research published in the Lancet Diabetes & Endocrinology shows.
During more than 60,000 hours of combined use of a novel artificial pancreas system, participants in a 12-week, multi-site clinical trial showed significant improvements in two key measures of well-being in people living with type 1 diabetes.
Researchers at the University of Cambridge have taken the first step towards developing a new form of treatment for type 1 diabetes which, if successful, could mean an end to the regular insulin injections endured by people affected by the disease, many of whom are children.
The new «smart cell patch» developed at UNC and NC State is a proof of principle to treat millions of people with type-1 and advanced type-2 diabetes.
A group of Russian scientists, including Dr Elena Kostryukova, the Head of the Laboratory of Postgenomic Research in Biology of the Scientific Research Institute of Physical-Chemical Medicine and a researcher at MIPT, and Maria Vakhitova, an MIPT postgraduate student, has discovered that the presence of certain bacteria in the gut may be linked to the development of type 2 diabetes.